Reckitt Benckiser and Orbis Biosciences have entered into an exclusive cooperation agreement to develop and commercialize novel technologies in the field of consumer healthcare. The global license agreement will leverage Orbis' Precision Particle Fabrication technology. The technology will enable new products for a leading segment of RB's product portfolio.
"We are proud to be partnering with one of the largest consumer products companies in the world to create differentiated products for their portfolio. The ability to add novel products to their extensive offering will provide patients the choice and flexibility they need to ease administration challenges," said Maria Flynn, chief executive officer and president of Orbis Biosciences.
"We are very excited to partner with the Orbis Biosciences talented team to strengthen further our innovation pipeline in strategic areas of our leading consumer health relief portfolio. At RB, we believe that vibrant partnerships are critical in delivering RB purpose of innovative solutions for Healthier Lives and Happier Homes," said Laurent Faracci, executive vice president of Category Development for RB Health.